8-K: Soleno Therapeutics Receives FDA Approval for VYKAT XR to Treat Hyperphagia in Prader-Willi Syndrome

Soleno Therapeutics announces FDA approval of VYKAT XR (diazoxide choline) extended-release tablets for treating hyperphagia in adults and children with Prader-Willi syndrome (PWS).

Summary

• Soleno Therapeutics has received FDA approval for VYKAT XR to treat hyperphagia in patients aged four years and older with Prader-Willi syndrome (PWS).
• VYKAT XR is expected to be available in the U.S. starting in April 2025.
• The approval was based on efficacy data from a Phase 3 trial (Study C602-RWP) where patients switching to placebo showed a statistically significant worsening of hyperphagia compared to those remaining on VYKAT XR.
• The drug has a well-established safety profile with over four years of data from clinical studies.
• The most common adverse reactions included hypertrichosis, edema, hyperglycemia, and rash.
• Soleno has launched Soleno OneTM, a patient support program, accessible via VykatXR.com or 1-833-SOLENO-1.
• Prader-Willi syndrome (PWS) affects approximately one in every 15,000 live births and is characterized by hyperphagia, leading to significant health risks.

Sentiment

Score: 9

Explanation: The document conveys a highly positive sentiment due to the FDA approval of VYKAT XR, a significant milestone for Soleno Therapeutics and the Prader-Willi syndrome community. The tone is optimistic, highlighting the potential of the drug to address an unmet medical need.

Positives

• VYKAT XR is the first approved therapy to address hyperphagia in individuals with Prader-Willi syndrome.
• Clinical trial data supports the efficacy and safety of VYKAT XR.
• The approval addresses a significant unmet need for individuals with PWS and their families.
• Soleno has launched a patient support program to facilitate access to VYKAT XR.

Negatives

• VYKAT XR has some common adverse reactions, including hypertrichosis, edema, hyperglycemia, and rash.
• The drug is contraindicated in patients with known hypersensitivity to diazoxide, other components of VYKAT XR, or to thiazides.
• Hyperglycemia, including diabetic ketoacidosis, has been reported with VYKAT XR use, requiring monitoring of blood glucose levels.

Risks

• Patients taking VYKAT XR may experience hyperglycemia, requiring regular monitoring of fasting glucose and HbA1c levels.
• There is a risk of fluid overload and edema, especially in patients with compromised cardiac reserve.
• The forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially.

Future Outlook

Soleno expects VYKAT XR to be available in the U.S. beginning in April 2025 and believes it will address the unmet needs of the PWS community.

Management Comments

• Anish Bhatnagar, M.D., Chief Executive Officer of Soleno, stated that the approval is a significant milestone for Soleno and the PWS community.
• Jennifer Miller, M.D., Professor of Pediatric Endocrinology at the University of Florida, Gainesville, expressed excitement about having VYKAT XR available to treat hyperphagia.
• Stacy Ward, Chief Executive Officer of the Prader-Willi Syndrome Association | USA, noted that VYKAT XR offers hope to families experiencing the challenges of hyperphagia.
• Susan Hedstrom, Executive Director of the Foundation for Prader-Willi Research, stated that the approval is a major step forward in changing the future for individuals navigating hyperphagia associated with PWS.

Industry Context

This announcement positions Soleno Therapeutics as a key player in the rare disease therapeutics market, specifically addressing Prader-Willi syndrome. The approval of VYKAT XR provides a new treatment option for a condition with limited existing therapies, potentially setting a new standard of care.

Comparison to Industry Standards

• Currently, there are limited FDA-approved treatments specifically targeting hyperphagia in PWS, making VYKAT XR a significant advancement.
• Other companies developing therapies for PWS include Zafgen (now Chondrial Therapeutics) and Millendo Therapeutics (which merged with another company), but their approaches differ, focusing on metabolic pathways or other aspects of the syndrome.
• The clinical trial results for VYKAT XR, demonstrating a statistically significant improvement in hyperphagia compared to placebo, are a key benchmark for evaluating its efficacy against potential future competitors.

Stakeholder Impact

• Shareholders: Positive impact due to the FDA approval and potential for increased revenue.
• Patients and Caregivers: Significant positive impact as VYKAT XR provides a new treatment option for hyperphagia in PWS.
• Employees: Positive impact due to the company's success and potential for growth.

Next Steps

• Soleno expects VYKAT XR to be available in the U.S. beginning in April 2025.
• Soleno will continue to support patients through the Soleno OneTM program.
• Soleno management hosted an investor conference call and webcast on March 26th to discuss the FDA approval.

Key Dates

Keywords

VYKAT XR, Soleno Therapeutics, Prader-Willi Syndrome, Hyperphagia, FDA Approval, Diazoxide Choline, Rare Diseases, PWS